Aspire Biopharma Warrant
ASBPW
29 hedge funds and large institutions have $151K invested in Aspire Biopharma Warrant in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 29 → 29 (0)
3.2% less ownership
Funds ownership: 30.92% → 27.71% (-3.2%)
46% less capital invested
Capital invested by funds: $277K → $151K (-$127K)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$342 |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$10 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$6.96K |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$4.93K |
| 3 |
CS
Clear Street
New York
|
-$2 |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BPA
26
Beacon Pointe Advisors
Newport Beach,
California
| $332 | – | – | – |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $279 | +$342 | +16,781 | New |
|
|
28
Barclays
London,
United Kingdom
| $145 | -$6.96K | -341,250 | -98% |
|
|
FTUS
29
Flow Traders U.S.
New York
| – | +$10 | +500 | +3% |
|
ASBPW Hedge Fund Activity: Q1 2026 in Review
29 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q1 2026, worth a combined $151K — down 46% from $277K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ASBPW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $342. The largest seller was Barclays, cutting an estimated $6.96K.
- 29 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $151K of Aspire Biopharma Warrant stock for Q1 2026, down 46% quarter-over-quarter.
- 1 fund opened new Aspire Biopharma Warrant positions in Q1 2026 and 0 closed out, a net change of +1 holder.
- The largest Aspire Biopharma Warrant buyer in Q1 2026 was Susquehanna International Group, an estimated $342 added.
- The largest Aspire Biopharma Warrant seller in Q1 2026 was Barclays, an estimated $6.96K sold.
Based on aggregated 13F filings for Q1 2026.